The Ketogenic Diet in the Treatment of Alzheimer's Disease

Summary

This research is a randomized, double-blind, placebo-parallel controlled, and multi-center clinical study in China, aiming to evaluate the tolerability, efficacy, and safety of JT821 (Ketogenic Diet) in the treatment of mild to moderate Alzheimer's disease.

The ketogenic diet (KD) is a low-carbohydrate, adequate protein and high-fat diet. KD was shown to be effective in treating different neurodegenerative diseases.

Conditions

• Alzheimer Disease

Interventions

DIETARY_SUPPLEMENT

Ketogenic diet

Ketogenic diet

DIETARY_SUPPLEMENT

placebo

placebo

Sponsors & Collaborators

• West China Hospital

  collaborator OTHER

• The First Affiliated Hospital of Zhengzhou University

  collaborator OTHER

• Tianjin Huanhu Hospital

  collaborator OTHER

• Shandong Provincial Hospital

  collaborator OTHER_GOV

• Peking University Third Hospital

  collaborator OTHER

• Shanghai Mental Health Center

  collaborator OTHER

• Beijing Tiantan Hospital

  collaborator OTHER

• Xiangya Hospital of Central South University

  collaborator OTHER

• First Affiliated Hospital of Chongqing Medical University

  collaborator OTHER

• Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

  collaborator OTHER

• The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

  collaborator OTHER

• Sichuan Provincial People's Hospital

  collaborator OTHER

• Brain Hospital Affiliated to Guangzhou Medical University

  collaborator UNKNOWN

• Sir Run Run Shaw Hospital

  collaborator OTHER

• Capital Medical University

  lead OTHER

Principal Investigators

• Jianping Jia, Dr. · Xuanwu Hospital, Beijing

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Model

PARALLEL

Eligibility

Min Age

50 Years

Max Age

85 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2024-02-23

Primary Completion

2025-09-10

Completion

2025-11-11

Countries

• China

Study Locations